Compare AKA & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKA | CRDL |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | Canada |
| Employees | 1650 | 18 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.6M | 120.9M |
| IPO Year | 2021 | 2017 |
| Metric | AKA | CRDL |
|---|---|---|
| Price | $9.99 | $0.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $19.75 | $8.55 |
| AVG Volume (30 Days) | 2.4K | ★ 764.3K |
| Earning Date | 11-04-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $600,208,000.00 | N/A |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | $5.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.42 | $0.88 |
| 52 Week High | $14.39 | $2.34 |
| Indicator | AKA | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 44.68 | 28.32 |
| Support Level | $8.54 | $0.94 |
| Resistance Level | $11.41 | $1.10 |
| Average True Range (ATR) | 0.35 | 0.06 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 38.79 | 20.33 |
a.k.a. Brands Holding Corp is a portfolio of fashion brands, including Princess Polly, Culture Kings, Petal & Pup, and mnml. Through these brands, the company reaches next-generation consumers who seek fashion inspiration on social media and mainly shop online. The portfolio consists of two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company generates the majority of its revenue from the United States.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.